New drug combo shows promise in Hard-to-Treat cancers

NCT ID NCT03829254

First seen Jan 12, 2026 · Last updated Jun 06, 2026 · Updated 25 times

Summary

This study tests a new drug called NUC-7738, given alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that haven't responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow cancer growth. About 135 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital)

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

  • Edinburgh Cancer Centre, Western General Hospital

    RECRUITING

    Edinburgh, EH4 2XU, United Kingdom

  • Freeman Hospital

    RECRUITING

    Newcastle, NE7 7DN, United Kingdom

  • Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital

    RECRUITING

    Preston, PR2 9HT, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    RECRUITING

    Oxford, OX3 9DU, United Kingdom

  • The Beatson West of Scotland Cancer Centre

    RECRUITING

    Glasgow, G12 0TN, United Kingdom

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    RECRUITING

    London, SW3 6JJ, United Kingdom

  • University College London Hospital

    RECRUITING

    London, NW1 2PG, United Kingdom

Conditions

The condition(s) this trial relates to.

cancer lymphoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.